AstraZeneca Pharma India is planning to sell a 64-acre site in Bengaluru, targeting about ₹3,400 crore as part of its land monetisation strategy. The parcel has attracted interest from developers including the Sattva Group, Aurobindo Pharma and RMZ, with negotiations expected to shape how quickly the company can unlock value from the asset.
JSW Group plans to monetize unused land it acquired with Akzo Nobel India, selling properties that are not currently needed for operations. The company expects the divestment could recover as much as half of its initial investment. It’s considering land sales in locations such as Thane to free up capital for broader business needs.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
